Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $405000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 5.59% to $405000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 28.03% increase, with the full-year FY2024 number at $1.7 million, down 14.54% from a year prior.
  • Depreciation & Amortization (CF) was $405000.0 for Q3 2025 at Theravance Biopharma, down from $409000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q1 2021 to a low of $405000.0 in Q3 2025.
  • A 5-year average of $678230.8 and a median of $432000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 36.51% in 2021, then decreased 4.22% in 2025.
  • Theravance Biopharma's Depreciation & Amortization (CF) stood at $1.5 million in 2021, then tumbled by 57.18% to $659000.0 in 2022, then dropped by 5.16% to $625000.0 in 2023, then plummeted by 32.48% to $422000.0 in 2024, then fell by 4.03% to $405000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Depreciation & Amortization (CF) are $405000.0 (Q3 2025), $409000.0 (Q2 2025), and $413000.0 (Q1 2025).